SCHEMBL17872156

SCHEMBL17872156

CC(C)(C)OC(=O)NCCCCN(CCCNC(=O)OCc1ccccc1)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.56
HTT P42858 1/20 0.53
SYK P43405 1/20 0.52
TGM2 P21980 1/20 0.51
KEAP1 Q14145 3/20 0.49
NFE2L2 Q16236 3/20 0.49
LMNA P02545 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
IDO1 P14902 1/20 0.48
CCR6 P51684 1/20 0.48
PAX8 Q06710 1/20 0.48
KLK7 P49862 2/20 0.48
KLK5 Q9Y337 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
FOLH1 Q04609 1/20 0.47
POLB P06746 1/20 0.47
MAPK1 P28482 1/20 0.47
SIGMAR1 Q99720 1/20 0.46
TDP1 Q9NUW8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9772169 0.92 MAPT (0.55) MAPTHTTSYKTGM2KEAP1
SCHEMBL19732512 0.92 CCR6 (0.59) MAPTHTTSYKTGM2KEAP1
SCHEMBL13480435 0.89 MAPT (0.65) MAPTHTTSYKTGM2KEAP1
SCHEMBL16789588 0.88 HTT (0.58) MAPTHTTSYKTGM2KEAP1
SCHEMBL15679441 0.88 MAPT (0.64) MAPTHTTSYKTGM2KEAP1
SCHEMBL13090607 0.88 MAPT (0.64) MAPTHTTSYKTGM2KEAP1
SCHEMBL20385193 0.88 MAPT (0.64) MAPTHTTSYKTGM2KEAP1
SCHEMBL20450596 0.87 CCR6 (0.48) MAPTHTTSYKTGM2KEAP1
SCHEMBL9766146 0.87 CCR6 (0.52) MAPTHTTSYKTGM2KEAP1
SCHEMBL13938297 0.87 HTT (0.65) MAPTHTTSYKTGM2KEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10434186-B2 Functionalized linear ligands and complexes thereof LUMIPHORE, INC. (US) 2019-10-08 US disclosed
US-20170360956-A1 FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF LUMIPHORE, INC. 2017-12-21 US disclosed
EP-3237429-A1 FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF Lumiphore, Inc. (US) 2017-11-01 EP disclosed
WO-2016106241-A1 FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF LUMIPHORE, INC. (US) 2016-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170360956-A1 FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF CLTB, CLTA, EPCAM MAPT 1163/4885HTT 1559/4885SYK 525/4885
US-10434186-B2 Functionalized linear ligands and complexes thereof CLTB, CLTA, EPCAM MAPT 1163/4885HTT 1559/4885SYK 525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.